KFF COVID-19 Vaccine Monitor: January 2023

Findings
  1. This is based upon adults who in the January 2023 KFF COVID-19 Vaccine Monitor survey reported they have ever been told by a doctor or health care provider that they are immunocompromised, or have a weakened or compromised immune system due to a disease, treatment, or medication they take. Estimates among immunocompromised people may differ from other clinical estimates of the share of immunocompromised adults based on specific conditions.

    ← Return to text

  2. KFF’s COVID-19 Vaccine Monitor data on vaccine and bivalent booster uptake is based on self-reported responses and may differ data from the Centers for Disease Control which is based on administered doses reported by specific jurisdictions and providers.

    ← Return to text

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.